This is not a novel answer, but I think it's really important to pay attention to the U.K. This is because of its obvious strengths as a national pharmacare example, and the kinds of things it's done that Dr. McCabe just mentioned, but also because of some of the tribulations associated with it. There have been challenges. When you concentrate decision-making in one place, the pressure on that organization to keep performing and make evidence-based decisions that aspire to some level of fairness will also increase. No system will be perfect, and I think there are important lessons about the institutional independence of NICE in particular that are worth paying attention to.
On May 30th, 2016. See this statement in context.